Tower Research Capital LLC (Trc) Eloxx Pharmaceuticals, Inc. Transaction History

Tower Research Capital LLC (Trc)

  • $3.68 Billion
  • Q3 2024

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 10, 2022
BUY
$0.15 - $7.2 $939 - $45,108
6,265 Added 48.14%
19,280 $3,000
Q2 2022

Aug 15, 2022
BUY
$0.24 - $0.58 $2,754 - $6,656
11,476 Added 745.68%
13,015 $4,000
Q1 2022

May 12, 2022
SELL
$0.4 - $0.72 $3,222 - $5,801
-8,057 Reduced 83.96%
1,539 $1,000
Q4 2021

Feb 14, 2022
BUY
$0.62 - $1.61 $5,949 - $15,449
9,596 New
9,596 $7,000
Q3 2021

Nov 15, 2021
SELL
$1.22 - $2.0 $12,946 - $21,224
-10,612 Closed
0 $0
Q2 2021

Aug 16, 2021
BUY
$1.35 - $3.36 $9,884 - $24,601
7,322 Added 222.55%
10,612 $21,000
Q1 2021

May 17, 2021
SELL
$3.02 - $4.54 $11,787 - $17,719
-3,903 Reduced 54.26%
3,290 $11,000
Q4 2020

Feb 16, 2021
SELL
$2.42 - $4.48 $54,208 - $100,352
-22,400 Reduced 75.69%
7,193 $29,000
Q3 2020

Nov 16, 2020
BUY
$2.53 - $3.4 $57,289 - $76,989
22,644 Added 325.86%
29,593 $78,000
Q2 2020

Aug 13, 2020
BUY
$1.56 - $3.65 $7,548 - $17,662
4,839 Added 229.34%
6,949 $21,000
Q1 2020

May 15, 2020
BUY
$1.96 - $7.96 $985 - $4,003
503 Added 31.3%
2,110 $4,000
Q4 2019

Feb 07, 2020
BUY
$3.19 - $7.56 $832 - $1,973
261 Added 19.39%
1,607 $12,000
Q3 2019

Nov 05, 2019
SELL
$4.37 - $9.91 $2,342 - $5,311
-536 Reduced 28.48%
1,346 $6,000
Q2 2019

Aug 13, 2019
SELL
$8.77 - $12.49 $54,733 - $77,950
-6,241 Reduced 76.83%
1,882 $19,000
Q1 2019

May 14, 2019
BUY
$10.45 - $13.94 $76,023 - $101,413
7,275 Added 857.9%
8,123 $95,000
Q4 2018

Feb 14, 2019
BUY
$10.43 - $17.39 $8,844 - $14,746
848 New
848 $10,000
Q3 2018

Nov 13, 2018
SELL
$11.95 - $19.63 $102,435 - $168,268
-8,572 Closed
0 $0
Q2 2018

Aug 15, 2018
BUY
$8.75 - $23.27 $75,005 - $199,470
8,572 New
8,572 $146,000

About Eloxx Pharmaceuticals, Inc.

ELOX Quotes by TradingView
  • Ticker ELOX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,656,200
  • Description
  • Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis p...
More about ELOX
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email